We are live on ! Find out more
NKGN

NKGen Biotech, Inc. Common Stock
NKGN

Delisted

NKGN was delisted on the 4th of March, 2025.

Back to rankings

41 hedge funds and large institutions have $109M invested in NKGen Biotech, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

18% more capital invested

Capital invested by funds: $92.1M → $109M (+$16.7M)

11% more funds holding

Funds holding: 37 → 41 (+4)

Holders
41
Holders Change
+4
Holders Change %
+10.81%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
6
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PC
Periscope Capital
Ontario, Canada
+$5.83M
2
KC
Kepos Capital
New York
+$5.11M
3
CFIA
Cantor Fitzgerald Investment Advisors
New York
+$2.48M
4
HIH
HRS Investment Holdings
New York
+$2.48M
5
CSS
Cubist Systematic Strategies
Connecticut
+$1.7M

Top Sellers

Rank Fund Capital Flow
1
AA
AQR Arbitrage
Connecticut
-$2.67M
2
AIMCA
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
-$1.94M
3
JG
Jefferies Group
New York
-$1.7M
4
OCM
Oaktree Capital Management
California
-$486K
5
EIP
Easterly Investment Partners
Massachusetts
-$485K
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$13.1M – – –
HCM
2
Highbridge Capital Management
New York
$10.9M – – –
RCM
3
Radcliffe Capital Management
Pennsylvania
$5.8M – – –
PC
4
Periscope Capital
Ontario, Canada
$5.8M +$5.83M +599,200 New
KC
5
Kepos Capital
New York
$5.08M +$5.11M +525,000 New
6CM
6
683 Capital Management
New York
$4.84M – – –
FTCM
7
Fir Tree Capital Management
New York
$4.84M – – –
SCC
8
Spring Creek Capital
Kansas
$4.46M – – –
SCM
9
Saba Capital Management
New York
$4.02M +$1.46M +150,200 +57%
Balyasny Asset Management
10
Balyasny Asset Management
Illinois
$3.88M – – –
Goldman Sachs
11
Goldman Sachs
New York
$3.53M – – –
UOC
12
UBS O'Connor
Illinois
$3.41M +$16.6K +1,709 +0.5%
TCA
13
Taconic Capital Advisors
New York
$3.39M – – –
Bank of America
14
Bank of America
North Carolina
$3.38M +$973K +100,000 +40%
PAMP
15
Polar Asset Management Partners
Ontario, Canada
$2.91M – – –
HIH
16
HRS Investment Holdings
New York
$2.47M +$2.48M +255,000 New
CFIA
17
Cantor Fitzgerald Investment Advisors
New York
$2.46M +$2.48M +255,000 New
SCM
18
Shaolin Capital Management
Florida
$2.46M – – –
D.E. Shaw & Co
19
D.E. Shaw & Co
New York
$2.45M – – –
Millennium Management
20
Millennium Management
New York
$2.36M +$1.46M +150,000 +160%
RCM
21
Rivernorth Capital Management
Florida
$1.94M – – –
CSS
22
Cubist Systematic Strategies
Connecticut
$1.69M +$1.7M +174,505 New
ACM
23
Atalaya Capital Management
New York
$1.45M – – –
CH
24
CVI Holdings
Delaware
$1.45M – – –
NRCM
25
Northern Right Capital Management
Connecticut
$1.45M – – –
1
2

NKGN Hedge Fund Activity: Q4 2021 in Review

41 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q4 2021, worth a combined $109M — up 18% from $92.1M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new NKGN positions and 3 closed out — a net gain of 4 holders — while 6 added to existing stakes and 5 trimmed.

The largest buyer was Periscope Capital, opening a new position worth an estimated $5.83M. The largest seller was AQR Arbitrage, cutting an estimated $2.67M.

  • 41 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q4 2021, up from 37 in Q3 2021.
  • Funds reported $109M of NKGen Biotech, Inc. Common Stock stock for Q4 2021, up 18% quarter-over-quarter.
  • 7 funds opened new NKGen Biotech, Inc. Common Stock positions in Q4 2021 and 3 closed out, a net change of +4 holders.
  • The largest NKGen Biotech, Inc. Common Stock buyer in Q4 2021 was Periscope Capital, an estimated $5.83M added.
  • The largest NKGen Biotech, Inc. Common Stock seller in Q4 2021 was AQR Arbitrage, an estimated $2.67M sold.

Based on aggregated 13F filings for Q4 2021.